Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Armata Pharmaceuticals (ARMP) EPS (Weighted Average and Diluted) (2016 - 2018)

Armata Pharmaceuticals (ARMP) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.24 as the latest value for Q4 2018.

  • Quarterly EPS (Weighted Average and Diluted) rose 32.28% to -$0.24 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was -$1.52 through Dec 2018, up 82.12% year-over-year, with the annual reading at -$4.8 for FY2025, 439.33% down from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.24 in Q4 2018 for Armata Pharmaceuticals, up from -$0.6 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.09 in Q3 2017 to a low of -$7.82 in Q2 2016.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$1.78 across 5 years, with a median of -$0.66 in 2014.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 2269.7% in 2016 and later skyrocketed 97.21% in 2017.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.44 in 2014, then dropped by 22.73% to -$0.54 in 2015, then plummeted by 1187.04% to -$6.95 in 2016, then surged by 94.9% to -$0.35 in 2017, then soared by 32.28% to -$0.24 in 2018.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ARMP at -$0.24 in Q4 2018, -$0.6 in Q3 2018, and -$0.68 in Q2 2018.